Pharmacological subgroup
L01F – MONOKLONALE ANTIKÖRPER UND ANTIKÖRPER-WIRKSTOFF-KONJUGATE
212Decisions
309Patient groups
Added benefit by patient group
- Major3
- Considerable54
- Minor37
- Non-quantifiable35
- Not proven178
- Lesser benefit2
Subgroups
- L01FA CD20 (Cluster of Differentiation 20)-Inhibitoren 3 decisions
- L01FB CD22 (Cluster of Differentiation 22)-Inhibitoren 1 decision
- L01FC CD38 (Cluster of Differentiation 38)-Inhibitoren 16 decisions
- L01FD HER2 (Humaner epidermaler Wachstumsfaktor-Rezeptor 2)-Inhibitoren 13 decisions
- L01FF PD-1/PD-L1 (Programmed Cell Death-1-Rezeptor/Programmed Cell Death-Ligand-1)-Inhibitoren 115 decisions
- L01FG VEGF/VEGFR (Vaskulärer endothelialer Wachstumsfaktor/-Rezeptor)-Inhibitoren 5 decisions
- L01FX Andere monoklonale Antikörper und Antikörper-Wirkstoff-Konjugate 56 decisions
- L01FY Kombinationen von monoklonalen Antikörpern und Antikörper-Wirkstoff-Konjugaten 3 decisions
Decisions, newest first
- 2026-10-01BlenrepBelantamab-MafodotinNot proven: 2 of 2 patient groups
- 2026-10-01BlenrepBelantamab-MafodotinNon-quantifiable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2026-10-01ZynyzRetifanlimabMinor
- 2026-10-01ZynyzRetifanlimabNon-quantifiable
- 2026-08-06ZiiheraZanidatamabNon-quantifiable
- 2026-07-16ElahereMirvetuximab SoravtansinConsiderable
- 2026-07-02LoqtorziToripalimabNot proven: 2 of 2 patient groups
- 2026-07-02LoqtorziToripalimabNot proven
- 2026-07-02MinjuviTafasitamabNon-quantifiable: 2 of 2 patient groups
- 2026-06-04OpdivoNivolumabConsiderable
- 2026-06-04LibtayoCemiplimabNon-quantifiable
- 2026-05-21KeytrudaPembrolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2026-03-19TevimbraTislelizumabNot proven
- 2026-03-19TevimbraTislelizumabNot proven
- 2026-03-19TevimbraTislelizumabNot proven
- 2026-03-19EnhertuTrastuzumab deruxtecanMinor
- 2026-03-19LynozyficLinvoseltamabNot proven: 2 of 2 patient groups
- 2026-02-19DarzalexDaratumumabMinor
- 2026-02-19DarzalexDaratumumabMinor
- 2026-02-19TivdakTisotumab VedotinNot proven: 3 of 3 patient groups
- 2026-02-19SarclisaIsatuximabNot proven
- 2026-01-22ImfinziDurvalumabConsiderable
- 2026-01-22ImfinziDurvalumabNot proven
- 2026-01-22OrdsponoOdronextamabNot proven
- 2026-01-22OrdsponoOdronextamabNot proven: 2 of 2 patient groups
- 2026-01-22ImfinziDurvalumabMinor
- 2025-12-18OpdivoNivolumabMinor
- 2025-12-18OpdivoNivolumabNot proven
- 2025-12-04OpdivoNivolumabNot proven
- 2025-12-04OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2025-11-20DatrowayDatopotamab deruxtecanNot proven: 3 of 3 patient groups
- 2025-11-06ColumviGlofitamabNot proven: 3 of 3 patient groups
- 2025-11-06ColumviGlofitamabNot proven: 2 of 2 patient groups
- 2025-10-16KeytrudaPembrolizumabNot proven
- 2025-10-16HetroniflySerplulimabNon-quantifiable
- 2025-10-16EnhertuTrastuzumab deruxtecanMinor
- 2025-08-21BlincytoBlinatumomabConsiderable
- 2025-08-21DarzalexDaratumumabConsiderable
- 2025-08-21BlincytoBlinatumomabNon-quantifiable
- 2025-08-21BlincytoBlinatumomabNon-quantifiable
- 2025-08-07JemperliDostarlimabNot proven
- 2025-08-07SarclisaIsatuximabMinor
- 2025-07-17RybrevantAmivantamabNot proven
- 2025-07-17RybrevantAmivantamabNot proven: 2 of 2 patient groups
- 2025-07-17RybrevantAmivantamabMinor
- 2025-06-18TevimbraTislelizumabNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven
- 2025-06-18TevimbraTislelizumabNot proven
- 2025-06-18TevimbraTislelizumabNot proven: 2 of 2 patient groups
- 2025-06-18TevimbraTislelizumabNot proven
- 2025-05-15DarzalexDaratumumabNot proven
- 2025-05-15KeytrudaPembrolizumabNot proven: 2 of 2 patient groups
- 2025-05-15KeytrudaPembrolizumabNon-quantifiable
- 2025-04-17TepkinlyEpcoritamabNot proven: 2 of 2 patient groups
- 2025-04-17VyloyZolbetuximabMinor
- 2025-04-03PadcevEnfortumab VedotinConsiderable: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2025-04-03KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNon-quantifiable: 1 of 3 patient groupsNot proven: 1 of 3 patient groups
- 2025-03-20TecentriqAtezolizumabConsiderable
- 2025-03-20TecentriqAtezolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-03-20KeytrudaPembrolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-03-06TepkinlyEpcoritamabNot proven
- 2025-02-20ImfinziDurvalumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-02-20ImfinziDurvalumabNot proven
- 2024-12-19OpdivoNivolumabNot proven
- 2024-10-17KeytrudaPembrolizumabNot proven: 2 of 2 patient groups
- 2024-10-17KeytrudaPembrolizumabNot proven
- 2024-07-04ElrexfioElranatamabNot proven: 2 of 2 patient groups
- 2024-06-20KeytrudaPembrolizumabMinor
- 2024-06-20KeytrudaPembrolizumabNot proven
- 2024-06-20KeytrudaPembrolizumabNot proven
- 2024-06-20PolivyPolatuzumab VedotinNot proven
- 2024-06-20PolivyPolatuzumab VedotinNot proven: 3 of 3 patient groups
- 2024-06-20JemperliDostarlimabMajor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-05-16DarzalexDaratumumabConsiderable
- 2024-05-16EnhertuTrastuzumab deruxtecanNot proven: 2 of 2 patient groups
- 2024-04-04TepkinlyEpcoritamabNon-quantifiable
- 2024-03-21OpdivoNivolumabNot proven
- 2024-03-07TalveyTalquetamabNon-quantifiable
- 2024-02-15TecvayliTeclistamabNot proven
- 2024-02-15TrodelvySacituzumab govitecanConsiderable
- 2024-02-01OpdivoNivolumabNon-quantifiable
- 2023-12-21OpdivoNivolumabNot proven
- 2023-12-21OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2023-11-02Zynlonta Loncastuximab tesirinNot proven: 2 of 2 patient groups
- 2023-10-19LibtayoCemiplimabNot proven: 2 of 2 patient groups
- 2023-10-19LibtayoCemiplimabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-10-05ImfinziDurvalumabMinor
- 2023-10-05ImfinziDurvalumabNot proven: 2 of 2 patient groups
- 2023-10-05ImfinziDurvalumabNot proven: 2 of 2 patient groups
- 2023-10-05Tremelimumab AstraZenecaTremelimumabNot proven: 2 of 2 patient groups
- 2023-10-05ImjudoTremelimumabNot proven: 2 of 2 patient groups
- 2023-07-20EnhertuTrastuzumab deruxtecanConsiderable
- 2023-07-20EnhertuTrastuzumab deruxtecanNot proven
- 2023-03-16PhesgoPertuzumab/TrastuzumabMinor
- 2023-03-16PerjetaPertuzumabMinor
- 2023-02-02KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-02-02EnhertuTrastuzumab deruxtecanConsiderable
- 2023-02-02EnhertuTrastuzumab deruxtecanNon-quantifiable
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2023-01-19KeytrudaPembrolizumabMinor
- 2022-12-15LunsumioMosunetuzumabNon-quantifiable
- 2022-12-01PadcevEnfortumab VedotinConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-10-20OpdivoNivolumabConsiderable
- 2022-10-20OpdivoNivolumabConsiderable
- 2022-10-20OpdivoNivolumabNot proven
- 2022-09-15DarzalexDaratumumabConsiderable
- 2022-07-07KeytrudaPembrolizumabNot proven: 2 of 2 patient groups
- 2022-07-07RybrevantAmivantamabNot proven: 2 of 2 patient groups
- 2022-05-19OpdivoNivolumabConsiderable
- 2022-05-19TrodelvySacituzumab govitecanMajor
- 2022-05-05KeytrudaPembrolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-05-05KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-03-18DarzalexDaratumumabConsiderable
- 2022-03-03MinjuviTafasitamabNon-quantifiable
- 2022-02-03DarzalexDaratumumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-01-20OpdivoNivolumabNot proven
- 2022-01-20DarzalexDaratumumabNot proven
- 2022-01-20LibtayoCemiplimabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-01-20LibtayoCemiplimabNot proven
- 2022-01-20BlincytoBlinatumomabMajor
- 2021-12-16AdcetrisBrentuximab VedotinMinor
- 2021-12-16EmplicitiElotuzumabConsiderable
- 2021-12-16OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-12-02JemperliDostarlimabNot proven
- 2021-11-19TecentriqAtezolizumabNot proven: 2 of 2 patient groups
- 2021-11-04SarclisaIsatuximabNot proven
- 2021-11-04SarclisaIsatuximabMinor
- 2021-11-04GazyvaroObinutuzumabNot proven
- 2021-11-04GazyvaroObinutuzumabNot proven
- 2021-11-04GazyvaroObinutuzumabNot proven
- 2021-10-21OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2021-09-16OpdivoNivolumabConsiderable
- 2021-09-16KeytrudaPembrolizumabNot proven
- 2021-09-16KeytrudaPembrolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-09-16KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-08-19BavencioAvelumabConsiderable
- 2021-07-15PhesgoPertuzumab/TrastuzumabNot proven
- 2021-07-15PhesgoPertuzumab/TrastuzumabNot proven
- 2021-07-15BlincytoBlinatumomabNon-quantifiable
- 2021-07-01OpdivoNivolumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-06-03YervoyIpilimumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-06-03OpdivoNivolumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-05-20TecentriqAtezolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-04-01ImfinziDurvalumabMinor
- 2020-12-03PoteligeoMogamulizumabNon-quantifiable
- 2020-10-01BavencioAvelumabNot proven
- 2020-08-20DarzalexDaratumumabNon-quantifiable
- 2020-08-20DarzalexDaratumumabMinor
- 2020-08-20CyramzaRamucirumabNot proven: 2 of 2 patient groups
- 2020-07-02KadcylaTrastuzumab EmtansinMinor
- 2020-05-14KeytrudaPembrolizumabConsiderable
- 2020-05-14KeytrudaPembrolizumabConsiderable: 2 of 2 patient groups
- 2020-05-14BavencioAvelumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2020-05-14KeytrudaPembrolizumabMinor
- 2020-04-02TecentriqAtezolizumabMinor
- 2020-04-02TecentriqAtezolizumabNot proven: 2 of 2 patient groups
- 2020-04-02TecentriqAtezolizumabNon-quantifiable
- 2020-04-02TecentriqAtezolizumabNot proven: 2 of 2 patient groups
- 2020-02-20CyramzaRamucirumabMinor
- 2020-02-06LibtayoCemiplimabNot proven: 2 of 2 patient groups
- 2019-09-19KeytrudaPembrolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2019-09-19KeytrudaPembrolizumabNon-quantifiable: 2 of 2 patient groups
- 2019-09-19KeytrudaPembrolizumabNon-quantifiable
- 2019-09-05AdcetrisBrentuximab VedotinNon-quantifiable
- 2019-08-15YervoyIpilimumabConsiderable: 2 of 2 patient groups
- 2019-08-15OpdivoNivolumabConsiderable: 2 of 2 patient groups
- 2019-08-15BlincytoBlinatumomabNon-quantifiable
- 2019-08-15BlincytoBlinatumomabNon-quantifiable
- 2019-06-20TecentriqAtezolizumabNot proven
- 2019-04-04ImfinziDurvalumabConsiderable
- 2019-04-04KeytrudaPembrolizumabNot proven
- 2019-02-21MylotargGemtuzumab OzogamicinNon-quantifiable
- 2018-12-20YervoyIpilimumabNot proven: 2 of 3 patient groupsLesser benefit: 1 of 3 patient groups
- 2018-12-20OpdivoNivolumabLesser benefit
- 2018-08-02YervoyIpilimumabNot proven
- 2018-07-05AdcetrisBrentuximab VedotinMinor
- 2018-03-16TecentriqAtezolizumabMinor
- 2018-03-16TecentriqAtezolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-03-16KeytrudaPembrolizumabConsiderable
- 2018-02-15DarzalexDaratumumabNot proven
- 2018-01-18BesponsaInotuzumab ozogamicinMinor
- 2017-12-21OpdivoNivolumabNot proven
- 2017-12-07BlincytoBlinatumomabConsiderable
- 2017-11-17OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-11-17KeytrudaPembrolizumabNot proven
- 2017-08-03KeytrudaPembrolizumabConsiderable
- 2017-06-15OpdivoNivolumabNot proven
- 2017-02-02KeytrudaPembrolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-01-19AdcetrisBrentuximab VedotinNon-quantifiable
- 2016-12-15OpdivoNivolumabNot proven: 2 of 2 patient groups
- 2016-12-01EmplicitiElotuzumabMinor
- 2016-10-20OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-10-20OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-10-20CyramzaRamucirumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-09-01CyramzaRamucirumabNot proven
- 2016-09-01CyramzaRamucirumabNot proven
- 2016-02-18PerjetaPertuzumabNot proven
- 2016-02-04KeytrudaPembrolizumabConsiderable: 2 of 3 patient groupsNot proven: 1 of 3 patient groups
- 2016-02-04OpdivoNivolumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-01-07OpdivoNivolumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2014-06-19KadcylaTrastuzumab EmtansinConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2014-06-05YervoyIpilimumabNot proven: 2 of 2 patient groups
- 2013-10-01PerjetaPertuzumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2013-05-16AdcetrisBrentuximab VedotinNon-quantifiable: 3 of 3 patient groups
- 2012-08-02YervoyIpilimumabConsiderable
Data status: 2026-10-29